Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18100304 | 0.93 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22808570 | 0.88 | ESR1 (0.44) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL18100343 | 0.87 | NOS3 (0.50) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL18100333 | 0.87 | SLC22A2 (0.49) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL11564425 | 0.83 | NOS3 (0.46) | ALDH1A1LMNAMAPTKMT2ANPC1 | |
| SCHEMBL18100336 | 0.83 | GAA (0.42) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL18100296 | 0.83 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL10533056 | 0.82 | LTA4H (0.49) | GAAADRA2A | |
| SCHEMBL10747714 | 0.82 | TRPV1 (0.43) | ALDH1A1MAPT | |
| SCHEMBL10934519 | 0.81 | CYP3A4 (0.43) | ALDH1A1LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280851-A1 | IMINOETHER COMPOUND, POLYESTER RESIN COMPOSITION, METHOD FOR PRODUCING CARBOXYLIC ACID ESTER, POLYESTER FILM, BACK SHEET FOR SOLAR CELL MODULE, AND SOLAR CELL MODULE | FUJIFILM CORPORATION (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20160280851-A1 | IMINOETHER COMPOUND, POLYESTER RESIN COMPOSITION, METHOD FOR PRODUCING CARBOXYLIC ACID ESTER, POLYESTER FILM, BACK SHEET FOR SOLAR CELL MODULE, AND SOLAR CELL MODULE | FUJIFILM CORPORATION (JP) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280851-A1 | IMINOETHER COMPOUND, POLYESTER RESIN COMPOSITION, METHOD FOR PRODUCING CARBOXYLIC ACID ESTER, POLYESTER FILM, BACK SHEET FOR SOLAR CELL MODULE, AND SOLAR CELL MODULE | BRS3, RAD1, RAD51 | ALDH1A1 1334/4885LMNA 621/4885MAPT 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.